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nase alfa therapy. A lung function test (“index”) separated a 2-year pre-index pe-
riod from a 2-year post-index period for which intercepts and slopes were
independently estimated. The comparator group included patients not yet re-
ported to have received dornase alfa; their index lung function test was associated
with their eighth or subsequent even-numbered birthday. Comparator patients
could contribute more than one set of pre- and post-index periods and could also
subsequently be included in the dornase alfa group. To account for the repeated
use of patients, variance components were estimated at the patient level as well as
the case level. Different subsets of the comparator cases were analyzed. RESULTS:
There were 2230 dornase alfa patients; the comparator group included 5970 cases
from 3517 patients. The estimated difference in change in slope was 0.73.31
(P0.020). Subsetting comparators to 4985 cases from 2836 patients not also in the
dornase alfa group gave 0.610.32 (P0.058); including each of those patients only
the last time eligible gave 0.680.36 (P0.059). Subsetting to 3662 cases from 2030
patients never on dornase alfa gave 0.320.34 (P0.35). Patient-level variance com-
ponents corresponding to difference in slope and difference in intercept were near
zero and so were dropped. CONCLUSIONS: In longitudinal observational studies,
patients should be included in each group for which they meet eligibility criteria,
possibly multiple times (with appropriate covariance structures). This avoids bias
from using future information to decide whether to include a patient and loss of
power from limiting cases unnecessarily.
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Numerous assumptions and techniques are necessary to perform meta-analysis.
Some overall structural guidelines and best practices on meta-analysis exist. How-
ever, few papers compare meta-analysis techniques in application. OBJECTIVES:
To review primary meta-analysis methods and their assumptions. After method-
ology review, we applied various meta-analysis techniques to the data of various
Bacille Calmette Guerin (BCG) vaccine studies and compared the results.
METHODS: Of the currently available meta-analysis techniques, the most basic
technique was applied first. Fixed effect models assume treatment effect homoge-
neity across studies. Then, random effect models and meta-regression were ex-
plored. Each technique explicitly models treatment heterogeneity. Lastly, the pos-
sibility of publication bias was tested through the use of a funnel plot. RESULTS:
Treatment effect estimates differed depending on the meta-technique applied.
When a fixed effect model was applied to estimate vaccination effectiveness
against tuberculosis, the log odds ratio was0.436 (confidence interval [CI]:0.528,
0.344). After testing for heterogeneity and fitting a random effects model, the
estimate was reduced to 0.741 (CI: 1.120, 0.352), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the effect
of treatment was reduced even further. CONCLUSIONS: Meta-analysis results are
sensitive to the selected studies and the methodology applied. Ensuring that
proper techniques are used is critical to estimate an unbiased outcome.
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OBJECTIVES: The ISPOR Task force (TF) on Good Research Practices for RCT-CEA
aims to foster improvements in the conduct of trial-based economic analysis. The
TF recognizes the sample size of randomized clinical trials (RCT) as one of the
challenges for trial-based economic analysis, as it is typically based on the primary
clinical outcomes only. In the case of vitreomacular traction (VMT), using RCT
individual patient-level data (IPD) to establish model starting distributions within
visual acuity (VA) health-states magnifies this challenge due to the small patient
numbers within each relevant VA health-state. Our objective was to develop an
innovative approach to robustly estimate patient within-category VA health-state
starting distributions.METHODS:A baseline VA-adjusted ordered logit model used
RCT IPD to predict a patient’s VA starting distribution as a function of treatment
allocation, macular hole, vitreomacular adhesion and previous vitrectomy status.
The observed ordinal variable consisted of 6 response categories i.e. VA state as a
function of an unmeasured, continuous, latent variable Y whose values determine
the patient’s VA-state dependent specific VA thresholds. RESULTS: Treatment al-
location was not a significant predictor for within-category VA health-state start-
ing distributions (at the 5% significance level), while MH, VMA and previous vitrec-
tomy status were significant and retained in the final model. The proportional odds
assumption was tested using a likelihood ratio test and confirmed that the rela-
tionship between each pair of VA health-states was the same (chi2  0.0906).
CONCLUSIONS: In eye-disorders like VMT, estimating within-category VA health-
state starting distributions requires a different approach due to the small number
of IPD in each VA health-state. Using an ordered logit model allows a more accurate
and robust estimation of within-category VA health-state starting distributions.
Macular hole, VMA and previous vitrectomy status were significant predictors of a
patient’s within-category VA health-state starting distribution, while treatment
allocation was not.
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OBJECTIVES: With the lack of alternative strategies for calculating the dose of
cytotoxic drugs in chemotherapy regimens, body surface area (BSA), despite well-
documented limitations, remains the most frequently used measure for dosing
guidelines. This is based on the assumption that physiological variables related to
drug metabolism and elimination, such as basal metabolic rate, renal and hepatic
function, vary between individuals according to BSA. BSA has traditionally been
calculated using a formula derived from Du Bois and Du Bois and published in 1916.
It is recognised this is probably not the most accurate method of calculating che-
motherapy doses, since the formula was derived from metabolic studies using a
small number of subjects. The practice of calculating chemotherapy dose adjusted
to BSA has drawn attention due to its lack of clear scientific basis, and lack of
applicability to different genders, disease states, and culture.METHODS:A system-
atic literature review was conducted using CRD methodology to establish the av-
erage BSA in cancer patients in Europe and the variability between genders, tumour
types, and cultures. RESULTS: Meta-analysis of the findings showed significant
differences between genders overall (females 1.72m2 vs males 1.88m2), between
different tumour types (range 1.68m2 to 1.93m2) and between different European
countries (range 1.74m2 to 1.83m2). However, statistical modelling showed that a
BSA of 1.80m2 approximated the population mean and identified the dispersion to
be 1.72-1.87m2 and was therefore a valid approximation for the majority of cancer
patients in Europe. CONCLUSIONS: Establishing a patient’s BSA is important in
determining the appropriate dosage regimen, but the population norm serves as a
useful basis for drugs administered in a fixed dose formulation.
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OBJECTIVES: In the context of today’s highly globalized environment, the interest
in the transferability of data of cost evaluation in health care has strongly intensi-
fied. A methodology is proposed to explore similarity versus dissimilarity of cost
evaluation data in adult sarcoma and hence their transferability across locations
(France and Italy). METHODS: Main steps are (i) definition of the objects (e.g. coun-
tries), identification of potential variability factors, selection of final variability fac-
tors, and construction of variability areas (e.g. unit cost of personnel); (ii) measure
of distances between the objects, determination of clusters and construction of a
hierarchical tree using the cluster analysis (CA); (iii) projection of the objects into
factorial planes and linkage between objects and areas of variability using principal
component analysis (PCA). Suggested methods are applied to an international cost
evaluation performed within the European network of excellence CONnectiveTIs-
suesCAncersNETwork (CONTICANET). RESULTS: Twelve objects and 16 areas of
variability were defined. CA shows four clusters meaning that data belonging to
different clusters are dissimilar (i) chemotherapy in France, (ii) follow-up with
relapse in Italy, (iii) diagnosis, surgery, chemotherapy, radiotherapy, and follow-up
without relapse in Italy, (iv) diagnosis, surgery, radiotherapy, follow-up without
relapse, and follow-up with relapse in France. PCA opposes (i) follow-up with re-
lapse in Italy to diagnosis, radiotherapy, and follow-up with relapse in France; (ii)
chemotherapy in France to follow-up without relapse in France. In sarcoma pa-
tients, transferability is then limited for chemotherapy during the initial treatment
in France and the follow-up with relapse in Italy. Diagnosis cannot be transferred
either between France and Italy regarding the quantities and unit costs of the
biopsies. CONCLUSIONS: Using CA and PCA enables health care professionals to
rapidly emphasize the variability of data and therefore to determine the transfer-
ability of cost evaluations across locations.
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OBJECTIVES: To investigate the knowledge, awareness and attitudes of cardiolo-
gists about the risk and benefits associated with medicines and medical devices
and equipment, and of how well they are regulated and communicated in Turkey.
METHODS:An on –line questionnaire has been developed which include questions
about the level of education and experience; perceptions of the risks and benefits
associated with medicines and medical devices; experiences of medicines and
medical devices; perceptions of and attitudes towards the regulation of medicines
and medical devices; attitudes towards the communication of information about
the risks and benefits associated with medicines and medical devices; usage of and
trust in communication of information about the risks and benefits associated with
medicines and medical devices. RESULTS: A total of 250 members of the Turkish
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